UROGRAFIN 30% 10mL injection ampoule

Land: Australien

Sprog: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Køb det nu

Indlægsseddel Indlægsseddel (PIL)
07-12-2020
Produktets egenskaber Produktets egenskaber (SPC)
24-08-2020

Aktiv bestanddel:

sodium amidotrizoate, Quantity: 40 mg/mL; amidotrizoate meglumine, Quantity: 260 mg/mL

Tilgængelig fra:

Bayer Australia Ltd

Lægemiddelform:

Injection, solution

Sammensætning:

Excipient Ingredients: water for injections; sodium calcium edetate

Indgivelsesvej:

Intravenous, Intraarticular

Enheder i pakken:

10mLx10

Recept type:

Not scheduled. Not considered by committee

Terapeutiske indikationer:

Intravenous and retrograde urography. Computerized tomography. Also for all angiographic examinations as well as for aminography, arthrography, intraoperative cholangiography, fistulography, hysterosalpingography, splenoportography, vesiculography and others. Urografin is not to be used for myelography, ventriculography of cisternography, since it is likely to provoke neurotoxic symptoms in these examinations.

Produkt oversigt:

Visual Identification: Clear solution, colour no darker than B5 or BY5 or Y5; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 5 Years; Container Temperature: Store below 30 degrees Celsius

Autorisation status:

Registered

Autorisation dato:

1992-09-22

Indlægsseddel

                                UROGRAFIN®
1
UROGRAFIN®
CONSUMER MEDICINE INFORMATION (CMI) SUMMARY
The full CMI on the next page has more details. If you are worried
about using this medicine, speak to your doctor or pharmacist.
1.
WHY AM I GIVEN UROGRAFIN?
UROGRAFIN contains the active ingredients sodium amidotrizoate and
amidotrizoate meglumine. UROGRAFIN is a contrast
agent used during an X-ray examination.
For more information, see Section 1. Why am I given UROGRAFIN? in the
full CMI.
2.
WHAT SHOULD I KNOW BEFORE I AM GIVEN UROGRAFIN?
Do not use if you have ever had an allergic reaction to UROGRAFIN or
any of the ingredients listed at the end of the CMI.
TALK TO YOUR DOCTOR, RADIOGRAPHER OR NURSE IF YOU HAVE ANY OTHER
MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE
PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING.
If you are to have an X-ray of your abdominal area or kidneys, you may
be asked to change your diet for 2 days prior and to not
eat (fast) after 6pm the evening before your procedure. It is
important that you still drink fluids as normal.
For more information, see Section 2. What should I know before I am
given UROGRAFIN? in the full CMI.
3.
WHAT IF I AM TAKING OTHER MEDICINES?
Some medicines may interfere with UROGRAFIN and affect how it works.
A list of these medicines is in Section 3. What if I am taking other
medicines? in the full CMI.
4.
HOW AM I GIVEN UROGRAFIN?
UROGRAFIN is injected by the doctor or radiographer into different
parts of your body depending on the area of your body to
be examined.
More instructions can be found in Section 4. How am I given UROGRAFIN?
in the full CMI.
5.
WHAT SHOULD I KNOW WHILE RECEIVING UROGRAFIN?
THINGS YOU
SHOULD DO
Tell your doctor, radiographer or nurse if you:
•
experience any of the severe symptoms of loss of consciousness or
heart attack, increase in heart
rate, difficulty breathing, low blood pressure and swelling of the
face, lips or tongue leading to
severe breathing difficulties and shock
•
experience any asthma symptoms e.g. chest tightening.
DRIVING OR USING
                                
                                Læs hele dokumentet
                                
                            

Produktets egenskaber

                                1
190213 Urografin PI
AUSTRALIAN PRODUCT INFORMATION
UROGRAFIN
®
Sodium amidotrizoate / Amidotrizoate meglumine
Injection
1
NAME OF THE MEDICINE
Sodium amidotrizoate / Amidotrizoate meglumine
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Urografin 30% contains 40 mg/mL sodium amidotrizoate and 260 mg/mL
amidotrizoate meglumine in
aqueous solution.
Urografin 76% contains 100 mg/mL sodium amidotrizoate and 660 mg/mL
amidotrizoate meglumine
in aqueous solution.
For the full list of
excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
Presentation
Urografin is a clear, colourless to faintly yellowish aqueous solution
for injection or infusion
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Intravenous and retrograde urography. Computerized tomography.
Also for all angiographic examinations as well as for amniography,
arthrography, intraoperative
cholangiography, fistulography, hysterosalpingography,
splenoportography, vesiculography and
others.
Urografin is not to be used for myelography, ventriculography of
cisternography, since it is likely to
provoke neurotoxic symptoms in these examinations.
4.2
DOSE AND METHOD OF ADMINISTRATION
General information
•
Dietary suggestions
In the case of abdominal angiography and urography, the diagnostic
yield is increased if the bowels
are emptied of faecal matter and gas. On the two days prior to the
examination patients should
therefore avoid flatulent food, in particular peas, beans and lentils,
salads, fruit, dark and fresh bread
and all kinds of uncooked vegetables. On the day before the
examination, patients should refrain
from eating after 6 p.m. Moreover, it can be appropriate to administer
a laxative in the evening. In
babies and young children, however, prolonged fasting and the
administration of a laxative before
the examination are contraindicated.
•
Hydration
Adequate hydration must be assured before and after contrast medium
administration. This applies
especially to patients with multiple myeloma, diabetes mellitus and
nephropathy, polyuria, ol
                                
                                Læs hele dokumentet